Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

Technology appraisal guidance
Reference number: TA127
Published: 22 August 2007
Last updated: 21 May 2024

TA127 Multiple sclerosis - natalizumab: Appendix A - Decision paper presented to the Institute's Guidance Executive

TA127 Multiple sclerosis - natalizumab: Appendix A - Decision paper presented to the Institute's Guidance Executive

TA127 Multiple sclerosis - natalizumab: Appendix A - Decision paper presented to the Institute's Guidance Executive
09 July 2013
(391.42 Kb 54 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 July 2013